Mature T-Cell and NK-Cell Lymphoma/Leukemia

Diseases /

Mature T-Cell and NK-Cell Lymphoma/Leukemia

Back to Diseases List

Associated Genetic Biomarkers

ALK
ALK Fusion
ATM
ATM Frameshift
ATM Nonsense
CD52 Expression
EBV Positive
LMP1 Expression Positive
MTCP1
MTCP1 Fusion
MTCP1 Overexpression
StrucGain(8)(q10qter)
TCL1A
TCL1A Fusion
TCL1A Overexpression
Trisomy 8
del(17)(p10)
dup(8)(q10qter)

Overview

Clinical Trials

View Clinical Trials for Mature T-Cell and NK-Cell Lymphoma/Leukemia

There are 13 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 5 are open and 8 are completed or closed. Of the trials that contain mature T-cell and NK-cell lymphoma/leukemia as an inclusion criterion, 5 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (0 open), and 2 are no phase specified (1 open).

EBV is the most frequent gene inclusion criterion for mature T-cell and NK-cell lymphoma/leukemia clinical trials [3].

Trials Investigating Mature T-Cell And NK-Cell Lymphoma/Leukemia by Gene and Recruiting Status

Cyclophosphamide, fludarabine, and allogeneic hematopoietic stem cell transplantation are the most common interventions in mature T-cell and NK-cell lymphoma/leukemia clinical trials.

Drugs Being Investigated in Mature T-Cell And NK-Cell Lymphoma/Leukemia Trials by Recruiting Status

Significant Genes in Mature T-Cell and NK-Cell Lymphoma/Leukemia

ABL1 +

ABL1 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain ABL1 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

AFF1 +

AFF1 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain AFF1 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

ALK +

ALK is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains ALK status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) [3].

BCL2 +

BCL2 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCL2 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

BCL6 +

BCL6 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

BCR +

BCR is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain BCR status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

CBFB +

CBFB is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains CBFB status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is no phase specified (0 open) [3].

DEK +

DEK is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain DEK status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

ELL +

ELL is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain ELL status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

FLT3 +

FLT3 is an inclusion eligibility criterion in 4 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 4 are closed. Of the trials that contain FLT3 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

KIT +

KIT is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is no phase specified (0 open) [3].

KMT2A +

KMT2A is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain KMT2A status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

MECOM +

MECOM is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain MECOM status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

MLLT1 +

MLLT1 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain MLLT1 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

MLLT10 +

MLLT10 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain MLLT10 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

MLLT3 +

MLLT3 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain MLLT3 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

MLLT4 +

MLLT4 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain MLLT4 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

MYC +

MYC is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYC status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MYH11 +

MYH11 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is no phase specified (0 open) [3].

NRIP3 +

NRIP3 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain NRIP3 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

NUP214 +

NUP214 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain NUP214 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

PBX1 +

PBX1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains PBX1 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain RPN1 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

RUNX1 +

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is no phase specified (0 open) [3].

RUNX1T1 +

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains RUNX1T1 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is no phase specified (0 open) [3].

TCF3 +

TCF3 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) [3].

TP53 +

TP53 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain TP53 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [3].

Disease Details

Parent(s)

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Mature T-Cell and NK-Cell Lymphoma/Leukemia

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Mature T-Cell and NK-Cell Lymphoma/Leukemia

Disease Details

References

About

Molecular Medicine

Content Types